Download
1743-422X-2-69.pdf 2,44MB
WeightNameValue
1000 Titel
  • Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
1000 Autor/in
  1. Vincent, Martin J. |
  2. Bergeron, Eric |
  3. Benjannet, Suzanne |
  4. Erickson, Bobbie R. |
  5. Rollin, Pierre E. |
  6. Ksiazek, Thomas G. |
  7. Seidah, Nabil G. |
  8. Nichol, Stuart T. |
1000 Erscheinungsjahr 2005
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2005-08-22
1000 Erschienen in
1000 Quellenangabe
  • 2(1):69
1000 Copyrightjahr
  • 2005
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/1743-422X-2-69 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/ |
1000 Ergänzendes Material
  • https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69#Sec13 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available. RESULTS: We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations. CONCLUSION: Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Chloroquine
lokal Severe Acute Respiratory Syndrome
lokal inhibition
lokal therapy
lokal Coronavirus
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/VmluY2VudCwgTWFydGluIEou|https://frl.publisso.de/adhoc/uri/QmVyZ2Vyb24sIEVyaWM=|https://frl.publisso.de/adhoc/uri/QmVuamFubmV0LCBTdXphbm5l|https://frl.publisso.de/adhoc/uri/RXJpY2tzb24sIEJvYmJpZSBSLg==|https://frl.publisso.de/adhoc/uri/Um9sbGluLCBQaWVycmUgRS4=|https://frl.publisso.de/adhoc/uri/S3NpYXplaywgVGhvbWFzIEcu|https://frl.publisso.de/adhoc/uri/U2VpZGFoLCBOYWJpbCBHLg==|https://frl.publisso.de/adhoc/uri/TmljaG9sLCBTdHVhcnQgVC4=
1000 Label
1000 Förderer
  1. Canadian Institutes of Health Research |
  2. Canadian PENCE |
1000 Fördernummer
  1. #MGC 64518; #MGP-44363
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Canadian Institutes of Health Research |
    1000 Förderprogramm -
    1000 Fördernummer #MGC 64518; #MGP-44363
  2. 1000 joinedFunding-child
    1000 Förderer Canadian PENCE |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6420180.rdf
1000 Erstellt am 2020-04-17T12:40:16.798+0200
1000 Erstellt von 122
1000 beschreibt frl:6420180
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet 2020-04-17T12:41:54.635+0200
1000 Objekt bearb. Fri Apr 17 12:41:32 CEST 2020
1000 Vgl. frl:6420180
1000 Oai Id
  1. oai:frl.publisso.de:frl:6420180 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source